Telix Pharmaceuticals Limited
TLX
Rank in Stocks
#4196
Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical... Telix Pharmaceuticals Limited is an Australian-based radiopharmaceutical company dedicated to pioneering molecularly targeted radiation (MTR) products. These innovations are developed for the diagnosis and treatment of various cancers and rare conditions, with its global presence encompassing Australia, Belgium, Japan, Switzerland, and the United States. The company's robust pipeline includes several leading candidates. TLX591-CDx is engineered for the diagnosis and treatment of metastatic castrate-resistant prostate cancer, while TLX66-CDx is designed for bone marrow conditioning and rare diseases. In advanced clinical development, TLX250-CDx is in Phase III trials for renal (kidney) cancer diagnosis and treatment, alongside TLX250 in Phase II for the same indication. TLX591 is also undergoing Phase III trials for metastatic castrate-resistant prostate cancer. For glioblastoma (brain cancer), TLX101 and TLX101-CDx are currently in Phase I/II studies, and TLX66 is in Phase I/IIa trials for bone marrow conditioning and rare diseases. Beyond these flagship programs, Telix is actively developing TLX592, a targeted alpha therapy candidate for prostate cancer. Its portfolio also features TLX591-Sx, a versatile PET tracer capable of both PET and fluorescent (optical) imaging, and TLX599-CDx, an investigational prostate cancer imaging agent utilizing single-photon emission computed tomography (SPECT). Strategic collaborations are integral to Telix's operations. This includes a significant license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for MTR product development, a scientific and clinical research alliance with Mauna Kea Technologies, and a strategic collaboration agreement with Lightpoint Medical, Ltd. Founded in 2015, the company's headquarters are located in North Melbourne, Australia.
Share Price
$11.21
Market Cap
$3.81B
Change (1 day)
2.06%
Change (1 year)
4.23%
Country
AU
Trade Telix Pharmaceuticals Limited (TLX)
Category
Healthcare
P/B ratio for Telix Pharmaceuticals Limited (TLX)
P/B ratio as of October 2026 TTM: 7.27
According to Telix Pharmaceuticals Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 7.27. At the end of 2023 the company had a P/B ratio of 21.61.
P/B ratio history for Telix Pharmaceuticals Limited from 2000 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.27 | -49.36% |
| 2024 | 14.35 | -33.60% |
| 2023 | 21.61 | -23.46% |
| 2022 | 28.23 | -97.21% |
| 2021 | 1.01K | 8,134.75% |
| 2020 | 12.31 | 138.38% |
| 2019 | 5.16 | 107.90% |
| 2018 | 2.48 | 47.14% |
| 2017 | 1.69 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2000 | 3.29 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 6.251 | -13.98% |
US
|
|
| 13.2547 | 82.39% |
US
|
|
| 4.208 | -42.10% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -14.93% |
NL
|
